KyungDong Pharm home
Prescription Medicines

Donepem Tab. 10mg

Product Category
Neuropsychiatric Medicines
Active Ingredients
donepezil hydrochloride
Appearance
A yellow, round, film-coated tablet.
Reimbursement Code
648104430
View Regulatory Information on the MFDS Portal ↗
1. Ingredient content
1 tablet
- Active ingredients:
Donepezil hydrochloride hydrate (USP) ----- 10.43mg
(10mg as donepezil hydrochloride)
- Additives (animal-derived ingredients): lactose hydrate (bovine, milk), magnesium stearate (bovine, beef tallow)
- Other additives: Microcrystalline cellulose, Opadry II Yellow (85F42138), Opadry Clear (02M49010), corn starch, hypromellose

2. Effectiveness
Treatment of Alzheimer's type dementia symptoms

3. Dosage and dosage
Adults: Administer donepezil hydrochloride at 5 mg once a day before bedtime. If you experience sleep disturbances such as strange dreams, nightmares, or insomnia, you may consider taking this medication in the morning. Since the concentration of donepezil reaches a steady state after 15 days of administration and the frequency of adverse reactions may be affected by the rate of dosage increase, a 5 mg dose should be administered for 4 to 6 weeks. After evaluating the clinical response during this period, the dose may be increased to 10 mg. When increasing the dose to 10 mg per day, administer while paying attention to adverse reactions in the digestive system. When you stop taking this drug, the effect gradually decreases, and there is no rebound effect due to sudden discontinuation of the drug.
Female patients over 85 years of age who are underweight: Careful monitoring is required as many adverse reactions occur. Underweight elderly women should not exceed 5 mg per day.
Children: There is no experience of use in children.

4. Precautions for use
1. Do not administer to the following patients.
1) Patients with hypersensitivity to donepezil hydrochloride, piperidine derivatives, or components of this drug
2) Pregnant women, women who may be pregnant, and lactating women
3) Since this drug contains lactose, it should not be administered to patients with genetic problems such as galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption.

2. Administer with caution to the following patients.
1) Patients with heart disease such as sinus predisposition syndrome, intraatrial and atrioventricular junction dysfunction (vagus nerve stimulation may cause bradycardia and arrhythmia).
2) Patients taking non-steroidal anti-inflammatory drugs or patients with a history of peptic ulcers (peptic ulcers may worsen due to stimulation of gastric acid secretion and digestive tract movement).
3) Patients with a history of asthma and obstructive pulmonary disease (symptoms may worsen due to contraction of bronchial smooth muscle and hypersecretion of bronchial mucus).
4) Patients with extrapyramidal disorders (Parkinson's disease, Parkinson's syndrome, etc.) (There is a possibility of causing or worsening symptoms due to hyperactivity of cholinergic nerves in the striatum.)

3. Adverse reactions
1) Treatment of mild to moderate Alzheimer's dementia symptoms
(1) The following are important adverse reactions of unknown frequency reported in clinical trials and believed to have a causal relationship with this drug. If the following symptoms appear, appropriate measures, such as discontinuation of medication, should be taken.
ⓛ Syncope, bradycardia, heart block, QT interval prolongation, myocardial infarction, heart failure
② Peptic ulcer, perforated duodenum, gastrointestinal bleeding
③ Hepatitis, liver dysfunction, jaundice
④ Cerebral seizures (epilepsy, convulsions, etc.), cerebral hemorrhage, cerebrovascular disorders
⑤ Extrapyramidal disorders: motor dysfunction, ataxia, dyskinesia, dystonia, tremor, involuntary movement, gait disorder, abnormal posture, speech disorder
⑥ Neuroleptic malignant syndrome: Symptoms such as akinetic mutism, extreme muscle stiffness, dysphagia, tachycardia, blood pressure fluctuations, and sweating may appear, and these symptoms are usually accompanied by fever. In this case, intensive treatment such as systemic therapy to reduce fever and supply of fluids and electrolytes should be administered along with discontinuation of the drug. An increase in white blood cells and serum CK (CPK) requires observation because it may cause renal dysfunction accompanied by myoglobinuria.
⑦ Since rhabdomyolysis may occur, muscle pain, weakness, and increased CK (CPK) in blood and urine should be carefully observed. Caution is required to determine whether renal dysfunction may occur due to rhabdomyolysis.
⑧ Difficulty breathing
⑨ Acute pancreatitis
⑩ Acute renal failure
⑪ Sudden death with unknown cause
(2) The following are adverse reactions reported in clinical trials and believed to have a causal relationship with this drug. The frequency of adverse reactions was categorized as very frequent (10% ≥), frequent (1 to <10%), occasionally (0.1 to <1%), rare (0.01 to <0.1%), and very rare (<0.01%).
*Table: refer to manual
(3) Regardless of the causal relationship with this drug, adverse reactions reported after administration of this drug are as follows.
① Vascular and lymphatic system: ecchymosis
② Nervous system: Abnormal dreams
(4) Domestic post-marketing survey results
As a result of a post-marketing use outcome survey conducted on 2,563 people over 6 years in Korea, adverse reactions were reported in 5.31% (136 cases/2,563 cases) regardless of causal relationship, and of these, 4.25% (109 cases/2,563 cases) were found to have a causal relationship with this drug.
Adverse reactions that were found to have a causal relationship with this drug (or for which a causal relationship cannot be ruled out) are listed in order of frequency of occurrence as follows.
Nausea was the most common at 1.72% (44 cases/2,563 cases), vomiting 0.82% (21 cases/2,563 cases), dizziness 0.62% (16 cases/2,563 cases), diarrhea 0.47% (12 cases/2,563 cases), insomnia 0.39% (10 cases/2,563 cases), and abdominal pain. The order was 0.31% (8 cases/2,563 cases). Loss of appetite, headache, fatigue, and extrapyramidal disorder were reported in 0.2% each, dystonia and urination disorder in 0.1% each, and anxiety, abnormal dreams, palpitations, lethargy, sweating, skin rash, aggressive behavior, tremor, gait disturbance, involuntary movement, decreased concentration, mental dullness, drowsiness, and cardiac arrest were reported in less than 0.1%.
Among these, one case of cardiac arrest was reported as a new adverse reaction that was not confirmed in pre-marketing clinical trials.
2) Treatment of severe Alzheimer’s type dementia symptoms
(1) Adverse reactions that caused discontinuation of administration
In controlled clinical trials, the drug discontinuation rate due to adverse reactions was 12% in the drug-treated group and 7% in the placebo group.
The most frequent adverse reactions leading to treatment discontinuation, defined as occurring in at least 2% of patients receiving this medicine and at least twice as frequently as in the placebo group, were decreased appetite (2% with this medicine versus 1% with placebo), nausea (2% versus less than 1%), diarrhea (2% versus 0%), and urinary tract infection (2% versus 1%).
(2) The most frequent adverse reactions likely to be related to the administration of this drug
The most common adverse reactions, defined as adverse reactions presumed to be due to the cholinergic effect of this drug, were diarrhea, loss of appetite, vomiting, nausea, and ecchymosis, which occurred at a frequency of at least 5% in patients receiving this drug and was more than twice that of the placebo group. These adverse reactions were mainly mild and transient and resolved without the need for dose adjustment during the treatment period. The following table lists treatment-emergent signs and symptoms that were reported in at least 2% of subjects receiving this drug in placebo-controlled trials and that occurred at a higher rate than those receiving placebo.
Adverse reactions reported in controlled clinical trials
*Table: refer to manual
(3) Other adverse reactions reported during clinical trials
The drug has been administered to more than 600 subjects with severe Alzheimer's disease in clinical trials lasting at least six months, including three double-blind, placebo-controlled trials (one of which was extended to an open-label trial). The table below includes all adverse reactions that occurred at least twice, but excludes adverse reactions already listed in the table above and those where the COSTART term is too general to provide useful information or has little relevance to the drug. Adverse reactions were classified according to body organ using the COSTART glossary and listed according to frequency of occurrence ≥1% or 0.1% to 1%:
These adverse reactions are not necessarily related to the administration of this drug, and in most cases, their frequency was similar to that observed in the placebo group in controlled clinical trials.
*Table: refer to manual
3) Among the adverse reactions voluntarily reported after marketing, those not mentioned above are as follows, and it is unclear whether they are related to this drug: abdominal pain, agitation, cholecystitis, confusion, convulsions, hallucinations, heart block (all types), hemolytic anemia, hepatitis, hyponatremia, neuroleptic malignant syndrome, pancreatitis, and rash.

4. General precautions
1) This drug is not approved for use in other forms of dementia or other forms of memory impairment (e.g., age-related cognitive decline).
Diagnostic caution is required to distinguish between Alzheimer's type and other types of dementia. Treatment should be initiated and supervised by a physician experienced in the diagnosis and treatment of Alzheimer's dementia. Diagnosis should be made according to recognized guidelines (e.g. DSM IV, ICD 10). Treatment with this drug should only be started when caregivers can regularly monitor the patient's drug use. Maintenance treatment should be continued only as long as it has a therapeutic effect on patient survival. That is, the clinical effectiveness of this drug should be reassessed regularly. Discontinuation of treatment should be considered when there is no longer evidence of treatment effect. Each individual's response to this drug cannot be predicted.
(1) Cardiovascular system: This drug has a vagal tonic effect due to its cholinesterase inhibition effect, which can cause bradycardia and symptoms such as heart block (sinoatrial node block or atrioventricular block), prolongation of the QT interval, and torsade de pointes. In particular, patients with a history or family history of QTc prolongation, patients on medication that affects the QTc interval, patients with heart disease (e.g., myocardial infarction, cardiomyopathy, heart valve disease, sinus failure syndrome or supraventricular ECG symptoms, intraatrial conduction disorder, atrioventricular junction conduction disorder, bradycardia) and electrolyte abnormalities (e.g., hypokalemia, hypomagnesemia) may develop serious arrhythmias, so special caution should be exercised when using this drug. Do it. ECG monitoring may be necessary. Syncope and seizures have been reported with the use of this drug in patients with cardiovascular disease.
(2) Digestive system: Cholinesterase inhibition can increase stomach acid or increase motility of the digestive tract, so patients with a history of peptic ulcers or taking non-steroidal anti-inflammatory drugs need to be monitored for symptoms. Clinical studies of this drug showed no increase in gastric ulcers or gastrointestinal bleeding compared to placebo.
(3) Urinary system: Although this drug was not shown in clinical trials, it may interfere with bladder urination due to cholinergic effects.
(4) Mental nervous system: By stimulating the movement of cholinergic nerves in the striatum through cholinergic effects, there is a possibility of inducing or worsening extrapyramidal disorder symptoms (diseases such as Parkinson's disease or Parkinson's syndrome) or causing seizures, but these seizures may also be caused by Alzheimer's disease.
(5) Respiratory system: It increases bronchial smooth muscle contraction or bronchial secretory function through cholinergic effects, so it should be prescribed with caution to patients with a history of asthma, bronchial disease, or obstructive pulmonary disease.
(6) Liver dysfunction: In a study of 10 patients with stable alcoholic liver cirrhosis, the clearance of this drug was reduced by 20% compared to 10 healthy subjects considering gender and age.
2) This drug has a mild to moderate effect on driving ability and ability to use machines. Dementia may result in decreased ability to drive or use machinery. Fatigue, dizziness, and muscle cramps may occur, especially when starting this medication or increasing the dose. Doctors should periodically check the ability of patients using this medicine to drive or use complex machinery.
3) Mortality rate in vascular dementia clinical trials:
Three 6-month clinical trials were conducted in patients with possible or probable vascular dementia (VaD) according to the NINDS-AIREN criteria. These criteria identified patients with purely vascular dementia and excluded patients with Alzheimer’s dementia. In the first study, mortality was 2/198 (1.0%) in the 5 mg group, 5/206 (2.4%) in the 10 mg group, and 7/199 (3.5%) in the placebo group. In the second study, mortality was 4/208 (1.9%) in the 5 mg group, 3/215 (1.4%) in the 10 mg group, and 1/193 (0.5%) in the placebo group. In the third study, mortality was 11/648 (1.7%) in the 5 mg group and 0/326 (0%) in the placebo group. Across the three vascular dementia studies, overall mortality was numerically higher in the treatment groups (1.7%) than in the placebo groups (1.1%), but the difference was not statistically significant. The main causes of death in both groups were various vascular conditions that may occur in older people with vascular disease. Analysis of all serious vascular adverse events showed no difference in incidence between the treatment and placebo groups.
In the overall analysis of the entire Alzheimer's clinical trial group (n=4146) and all forms of dementia clinical trial groups, including Alzheimer's disease and vascular dementia (total n=6888), the mortality rate in the placebo group was numerically higher than that in the medication group.
4) During anesthesia: This drug, a cholinesterase inhibitor, tends to maximize the action of succinalcholine-type muscle relaxants during anesthesia.

5. Interaction
1) This drug is mainly metabolized by CYP3A4, with CYP2D6 partially involved. The degree of inhibition or induction is not yet known, but caution should be exercised when combined with the following drugs.
(1) CYP3A4 inhibitors (e.g. itraconazole, erythromycin) and CYP2D6 inhibitors (e.g. quinidine, fluoxetine) may interfere with the metabolism of this drug and increase its efficacy.
(2) CYP3A4 and CYP2D6 inducers (e.g. rifampicin, phenytoin, carbamazepine, dexamethasone, phenobarbital, alcohol) may increase the metabolism of this drug and reduce its efficacy.
2) This drug may enhance the action of suxamethonium muscle relaxant or other neuromuscular blockers.
3) Caution should be exercised when co-administering with cholinergic drugs (e.g. capronium, bethanechol, aclatonium, nafadisylate) or acetylcholinesterase inhibitors (e.g. ambenonium, distigmine, pyridostigmine, neostigmine) as concurrent use may increase cholinergic effects such as vagus nerve stimulation.
4) This drug and anticholinergic drugs (e.g. atropine, scopolamine, trihexyphenidyl, pyroheptin, biperidine) may reduce the efficacy of the drug due to antagonistic effects.
5) This drug does not inhibit the metabolism of theophylline, warfarin, cimetidine, and digoxin, and the metabolism of this drug is not affected by combined use with digoxin or cimetidine.
6) Co-administration with drugs such as beta-blockers that affect cardiac conduction may cause synergistic effects.
7) Concurrent use with NSAIDs may cause peptic ulcers by increasing secretion of gastric acid due to cholinergic effects.
8) Cases of QT interval prolongation and torsade de pointes have been reported in relation to donepezil. Caution should be exercised when coadministering the following drugs that prolong the QTc interval, and ECG monitoring may be required:
Class IA antiarrhythmic drugs (e.g. quinidine)
Class III antiarrhythmic drugs (e.g. amiodarone, sotalol)
Some antidepressants (such as citalopram, escitalopram, and amitriptyline)
Other antipsychotics (e.g. phenothiazine derivatives, sertindole, pimozide, ziprasidone)
Some antibiotics (such as clarithromycin, erythromycin, levofloxacin, and moxifloxacin)

6. Administration to pregnant and lactating women
1) Pregnancy: There is no clinical data on this drug in pregnant women, so this drug should not be used during pregnancy unless absolutely necessary.
Although it did not cause malformations in animal tests, it did affect the survival and stillbirth rates of young pups. The potential risk to pregnant women is unknown.
2) Nursing mothers: This drug passes into rat breast milk. It is not known whether this drug passes into breast milk. Since there are no research results on lactating women, this drug should not be used in lactating women, and if it must be administered, breast-feeding should be discontinued during the treatment period.

7. Administration to children
Safety in children has not yet been established (there is no experience of use in children).

8. Effect on clinical test values
As a result of clinical trials, there were no notable abnormalities in laboratory values, but administration of this drug may slightly increase the concentrations of muscle CK (CPK), LDH, AST, ALT, γ-GPT, ALP, BUN, total cholesterol, triglycerides, amylase, and urine amylase.

9. Treatment in case of overdose
1) Symptoms: Overdosage of cholinesterase inhibitors may result in risks related to cholinergic effects such as severe nausea, vomiting, hypersalivation, sweating, bradycardia, hypotension, respiratory depression, weakness, and convulsions. Muscle weakness may occur and respiratory muscles may relax, leading to death.
In animal experiments on mice and rats, the median lethal dose was 45 mg/kg and 32 mg/kg, which are 225 and 160 times the maximum dose for humans (10 mg/day), respectively. Symptoms of cholinergic stimulation compared to dose in animal experiments included decreased voluntary behavior, prone posture, staggering gait, tears, clonic convulsions, decreased breathing, salivation, pupil constriction, fasciculation, and decreased body surface temperature.
2) Treatment: In case of overdose, treat in the usual manner. Tertiary anticholinergics (e.g. atropine sulfate) may be used as an antidote for overdose of this drug. In the case of atropine, administer intravenously at an initial dose of 1.0 to 2.0 mg, then increase the dose according to clinical response. However, there have been reports of atypical reactions in blood pressure and heart rate when quaternary anticholinergics and cholinergic drugs (e.g., glycopyrrolate) were coadministered. It is not known whether donepezil hydrochloride and its metabolites are removed by dialysis (hemodialysis, peritoneal dialysis, or hemofiltration).

10. Precautions for storage and handling
1) Keep out of reach of children.
2) Be careful because changing it into another container may cause an accident or is undesirable in terms of maintaining quality.

11. Pharmaceutical equivalence test information Note 1
A. The test drug donepezil hydrochloride tablets 10 mg [Jeil Pharmaceutical Co., Ltd.] and the reference drug Aricept tablets 10 mg (donepezil hydrochloride) [Daewoong Pharmaceutical Co., Ltd.] were administered orally once on an empty stomach to healthy adults in a 2 In this case, the 90% confidence interval of the mean difference was within log 0.8 to log 1.25, proving biological equivalence.
*Table: refer to manual
B. In accordance with Article 7, Paragraph 2 of the Pharmaceutical Equivalence Test Standards, comparative dissolution test data were submitted for the test drug Donepezil Hydrochloride Tablets 5 mg [Jeil Pharmaceutical Co., Ltd.] with the reference drug Donepezil Hydrochloride Tablets 10 mg [Jeil Pharmaceutical Co., Ltd.], and the dissolution pattern was equivalent to that of the reference drug. Accordingly, bioequivalence was proven with the relevant data.
Note 1. Every stage of manufacturing for this medicine is contracted to Jeil Pharmaceutical Co., Ltd., using the same raw materials and manufacturing methods as its donepezil hydrochloride 5 mg and 10 mg tablets.

5. How to save
Airtight container, stored at room temperature (1~30℃)

6. Packaging unit
30 tablets/bottle

7. Period of use
36 months from date of manufacture

Product Updates

Total 2items

No.Product NameDetailsDate of ChangeDownload
2Donepem Tab. 10mgDosage and precautions for use2023.07.01Donefem Tablet 10mg Changes in dosage and precautions for use (draft).pdfFile under review
1Donepem Tab. 10mgPrecautions for use2022.07.26Change order_Precautions for use_Donepem tablets 10 mg (including change comparison table).pdfFile under review